Therapeutic effects of cefozopran against experimental mixed urinary tract infection with Enterococcus faecalis and Pseudomonas aeruginosa in mice.
The therapeutic activity of cefozopran, a new semisynthetic parenteral cephalosporin, was compared with those of ceftazidime, ampicillin, imipenem/cilastatin and ofloxacin against an ascending mixed urinary tract infection induced in mice with Enterococcus faecalis TN2005 and Pseudomonas aeruginosa P9. Cefozopran significantly reduced viable cell counts of both organisms in the kidneys. Ceftazidime, imipenem/cilastatin and ofloxacin were active against only P. aeruginosa, and ampicillin was active against only E. faecalis.
Tsuchimori
N
N
Pharmaceutical Research Laboratories III, Takeda Chemical Industries, Ltd, Yodogawa-ku, Osaka, Japan. tsuchimo@lab.takeda.co.jp
Yamazaki
T
T
Okonogi
K
K
D000667:Ampicillin / Q000627:therapeutic use; D000818:Animals; D002442:Ceftazidime / Q000494:pharmacology / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use*; D015377:Cilastatin / Q000627:therapeutic use; D013293:Enterococcus faecalis; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D015378:Imipenem / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D008808:Mice, Inbred CBA; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*; D000097586:Cefozopran
D000667:Ampicillin; D002442:Ceftazidime; D002511:Cephalosporins; D015377:Cilastatin; D015378:Imipenem; D015242:Ofloxacin; D000097586:Cefozopran